The UK Medicines and Healthcare products Regulatory Agency (MHRA) presented the next phase of its strategy for regulating medical technologies and artificial intelligence at the AdvaMed 2026 conference. The event brought together leaders of the American healthcare industry, to whom the regulator outlined plans for further development of the regulatory framework. MHRA has traditionally played a key role in the certification and control of medical devices in the United Kingdom, and in recent years the agency has been actively working to adapt regulatory mechanisms to rapidly evolving technologies, including artificial intelligence solutions used in patient diagnosis, treatment, and monitoring. The presentation at AdvaMed — the largest industry platform bringing together medical equipment manufacturers from the US — underscores the British regulator's commitment to international dialogue and harmonization of standards. This is particularly relevant for companies launching their products in markets on both sides of the Atlantic and facing the need to comply with requirements of different jurisdictions. MHRA's new agenda is expected to address issues of accelerated approval for innovative medical technologies, safety assessment of artificial intelligence algorithms used in clinical practice, as well as the creation of more flexible post-market surveillance mechanisms. Such initiatives reflect a global trend toward reassessing regulatory approaches in light of the rapid development of digital and AI solutions in medicine. For medical device manufacturers and AI systems developers, dialogue with MHRA at a platform like AdvaMed provides an opportunity to gain early insight into the direction of regulatory policy and adjust strategies for bringing products to the British market accordingly.